We're currently fundraising! Become an early investor in Bioverge to own an expanding portfolio of leading TechBio startups through a single investment 🔬! Learn more and invest today 💸!

Media

Yieyxrsfsiycizcbnuds
Media

The Bioverge Podcast: Evolving Failures in an Evolving Pandemic and What Needs to Be Done

Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

Continue Reading >
8nys0ffnsigxpq6obfzw
Media

The Bioverge Podcast: Bridging the Translational Science Divide

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

Continue Reading >
Wfajhg7jquawlzel0nf1
Media

The Bioverge Podcast: Democratizing Entrepreneurship

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

Continue Reading >
Bkect61tqqoepbcvxb2j
Media

The Bioverge Podcast: Managing the Challenges of Scaling Cell and Gene Therapies

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.

Continue Reading >
F7xqdtj7ssypvkwzlynj
Media

The Bioverge Podcast: Advancing a Pipeline of Off-The-Shelf Cell Therapies

Brian Culley, CEO of Lineage Cell Therapeutics, sits down with Neil to discuss his company’s efforts to develop off-the-shelf cell therapies to treat degenerative retinal disease, spinal cord injury, and cancer.

Continue Reading >
Vxbajvltmmgvzykrrvsr
Media

The Bioverge Podcast: Weighing the Strengths and Weakness of Various COVID-19 Vaccines

Craig Laferrière head of vaccine development for Novateur Ventures, joins Neil to discuss the relative strengths and weaknesses of the different COVID-19 vaccines in use and in development.

Continue Reading >
Xuexxcxvsb6grvsigykr
Media

The Bioverge Podcast: Improving Epilepsy Outcomes with Digital Health Technology

Rachel Kuperman, CEO of Eysz, sits down with Neil to discuss her company’s efforts to develop a digital health platform using passive eye-movements as input to measure, diagnose, and predict neurological disease starting with epilepsy.

Continue Reading >
90di3aalreeft2qoafxi
Media

The Bioverge Podcast: Removing Toxins from Cerebrospinal Fluid to Treat Neurodegenerative Diseases

Anthony DePasqua, CEO of EnClear Therapies, sits down with Neil to discuss the company’s technology in development to remove toxic proteins from cerebrospinal spinal fluid to treat patients with ALS and other neurodegenerative conditions.

Continue Reading >
Kyevtprqr62oqrseuluk
Media

The Bioverge Podcast: Decoding the World

Arvind Gupta, founder of IndieBio and co-lead of the engineering biology practice at the venture capital firm Mayfield, and Po Bronson, author and managing director and partner at IndieBio, sit down with Neil to discuss their new book Decoding the World, IndieBio, and the future of biotech.

Continue Reading >
Ts4ljonkq8awogjjt6ft
Media

The Bioverge Podcast: Making Long-Term Bets on Longevity

About ten years ago, futurist Sonia Arrison in her book “100 Plus” explored the coming age of longevity and the broad impacts it would have. Now, as a venture investor, she’s backing companies that are positively impacting longevity through her 100 Plus Capital. In this episode, Neil ...

Continue Reading >